CTIS2022-502982-49-00招募中1 期
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer - CP-MGD019-02
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Metastatic castration-resistant adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features., Participants must have = 1 metastatic (measurable or non-measurable per PCWG3) lesion., Participant has prostate cancer progression at study entry based on PCWG3 criteria., Participant shows evidence of disease progression after receiving at least 1 prior androgen receptor axis-targeted therapy (ARAT) regimen (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide)., Patients with known history of documented breast cancer gene (BRCA) mutation (germline or somatic) must have received an approved poly ADP ribose polymerase (PARP) inhibitor regimen., Participants must have adequate performance status, life expectancy and laboratory values.
排除标准
- •Any condition preventing participant’s ability to receive, tolerate, or comply with the planned treatment or study procedures., Received prior chemotherapy for mCRPC or prior treatment with checkpoint inhibitors for prostate cancer., Current active or chronic infections., Any clinically significant heart, lung, or gastrointestinal disorders., Allergy to any of the study treatments or components of the study treatments.
研究者
相似试验
进行中（未招募）
1 期
A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-oncology Therapy after Prior Treatment with Tyrosine Kinase InhibitorsEUCTR2018-003151-38-PLBristol-Myers Squibb International Corporation250
招募中
1 期
A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-oncology Therapy after Prior Treatment with Tyrosine Kinase InhibitorsAdvanced Hepatocellular CarcinomaMedDRA version: 20.0Level: PTClassification code: 10073071Term: Hepatocellular carcinoma Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10077738Term: Hepatocellular carcinoma metastatic Class: 10029104CTIS2023-503519-13-00Bristol Myers Squibb International Corporation250
进行中（未招募）
2 期
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsAdvanced Hepatocellular CarcinomaJPRN-jRCT2031200442David Perez Callejo24
进行中（未招募）
1 期
A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-oncology Therapy after Prior Treatment with Tyrosine Kinase InhibitorsAdvanced Hepatocellular CarcinomaMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077738Term: Hepatocellular carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003151-38-CZBristol-Myers Squibb International Corporation357
进行中（未招募）
1 期
A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic SyndromeEUCTR2007-005584-10-GBPharmion Corporation180